Competitor launches oral GLP-1 weight-loss pill within 12 months

At least one major pharmaceutical competitor (e.g., Eli Lilly, Pfizer, or Amgen) will launch an oral GLP-1 weight-loss pill within 12 months, targeting Novo Nordisk’s market lead.

adoption · Prediction Market

Implied probability (Yes)

55%

Closes

2027-07-06

More adoption markets

• OpenAI Codex mobile usage exceeds desktop by Q1 2027 — 72% Yes
• OpenAI Codex mobile usage surpasses desktop within 6 months — 70% Yes
• PGA Tour Shop app downloads increase 25% YoY in 2026 — 68% Yes
• Bluesky's AT Protocol gains adoption by 3 major third-party apps by Q1 2027 — 55% Yes
• iOS 27 public release sees 20% adoption within first 6 weeks — 60% Yes
• Animal rights NGOs expand operations in Uganda by 2027 — 75% Yes
• Passive ETF inflows into SpaceX exceed $1.5 billion by October 2026 — 55% Yes
• Anthropic's enterprise AI share surpasses 30% by Q4 2026 — 75% Yes

Browse all adoption markets →